A Study of AAVB-039 in Participants With Stargardt Disease (STGD1)
NCT ID: NCT07161544
Last Updated: 2026-01-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1/PHASE2
75 participants
INTERVENTIONAL
2025-09-29
2032-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Tolerability of ZVS101e in Patients With Bietti 's Crystalline Dystrophy
NCT05714904
Intravitreal Bevacizumab for Choridal Neovascularization Secondary to Age-Related Macular Degeneration
NCT00556348
Long-term Outcome of Zonal Outer Retinopathy in Punctate Inner Choroidopathy or Multifocal Choroiditis
NCT03897192
Long-term Outcome of Punctate Inner Choroidopathy or Multifocal Choroiditis With Active Choroidal Neovascularization Managed With Anti-vascular Endothelial Growth Factor
NCT03793400
Efficacy and Safety of Intravitreal Bevacizumab in the Treatment of Choroidal Neovascular Membranes Associated to High Myopia
NCT00967850
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1
AAVB-039 dose level 1 (low dose)
AAVB-039
Single subretinal administration
Cohort 2
AAVB-039 dose level 2 (mid dose)
AAVB-039
Single subretinal administration
Cohort 3
AAVB-039 dose level 3 (high dose)
AAVB-039
Single subretinal administration
Cohorts 4-5
AAVB-039 dose level 1, 2 or 3
AAVB-039
Single subretinal administration
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AAVB-039
Single subretinal administration
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Willingness to adhere to protocol per informed consent
Exclusion Criteria
* Participation in a clinical study with another Investigation Medicinal Product
* Previous participation in another gene or cell therapy trial
* Any condition that would preclude subretinal surgery
* Complicating ocular and/or systemic diseases
8 Years
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AAVantgarde Bio Srl
INDUSTRY
AAVantgarde Bio UK Ltd
UNKNOWN
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Retina Consultants of Texas
Bellaire, Texas, United States
Retina Foundation of the Southwest
Dallas, Texas, United States
Moorfields Eye Hospital NHS Foundation Trust
London, England, United Kingdom
The Retina Clinic
London, England, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
039-101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.